TickerFacts.

Iovance Biotherapeutics, Inc. (IOVA): Cost of Revenue

Annual figures by period end, from SEC filings.

$173.18M
Year ended 2025-12-31
2023-12-31: $1.03M2024-12-31: $93.25M2025-12-31: $173.18M$173.18M
2023-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$173.18M+85.7%2026-02-24, From 2025-01-01
2024-12-31$93.25Mn/m2026-02-24, From 2024-01-01
2023-12-31$1.03Mn/a2026-02-24, From 2023-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Iovance Biotherapeutics, Inc. (IOVA)2025-12-31$173.18M+85.7%
Vericel Corp (VCEL)2025-12-31$70.66M+8.5%
Adaptive Biotechnologies Corp (ADPT)2025-12-31$71.36M-1.0%
Twist Bioscience Corp (TWST)2025-09-30$185.57M+3.3%
Adaptimmune Therapeutics PLC (ADAPY)2024-12-31$70.0Kn/a
Immunocore Holdings plc (IMCR)2025-12-31$5.09M+86.3%
REGENXBIO Inc. (RGNX)2024-12-31$33.57M-9.8%
ADMA Biologics, Inc. (ADMA)2025-12-31$217.41M+5.1%
Agenus Inc (AGEN)2025-12-31$1.02M+110.3%

Compare IOVA, VCEL, ADPT, TWST side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗